|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fernández-Medarde A and Santos E: Ras in
cancer and developmental diseases. Genes Cancer. 2:344–358. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reddy EP, Reynolds RK, Santos E and
Barbacid M: A point mutation is responsible for the acquisition of
transforming properties by the T24 human bladder carcinoma
oncogene. Nature. 300:149–152. 1982. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adjei AA: Blocking oncogenic Ras signaling
for cancer therapy. J Natl Cancer Inst. 93:1062–1074. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cochet O, Kenigsberg M, Delumeau I,
Virone-Oddos A, Multon MC, Fridman WH, Schweighoffer F, Teillaud JL
and Tocqué B: Intracellular expression of an antibody
fragment-neutralizing p21 ras promotes tumor regression. Cancer
Res. 58:1170–1176. 1998.PubMed/NCBI
|
|
7
|
Prendergast GC, Davide JP, deSolms SJ,
Giuliani EA, Graham SL, Gibbs JB, Oliff A and Kohl NE:
Farnesyltransferase inhibition causes morphological reversion of
ras-transformed cells by a complex mechanism that involves
regulation of the actin cytoskeleton. Mol Cell Biol. 14:4193–4202.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kohl NE, Omer CA, Conner MW, Anthony NJ,
Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton
K, et al: Inhibition of farnesyltransferase induces regression of
mammary and salivary carcinomas in ras transgenic mice. Nat Med.
1:792–797. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Canevari S, Biocca S and Figini M: Re:
Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer
Inst. 94:1031–1032; author reply 1032. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mhashilkar AM, Bagley J, Chen SY, Szilvay
AM, Helland DG and Marasco WA: Inhibition of HIV-1 Tat-mediated LTR
transactivation and HIV-1 infection by anti-Tat single chain
intrabodies. EMBO J. 14:1542–1551. 1995.PubMed/NCBI
|
|
11
|
Duan L, Bagasra O, Laughlin MA, Oakes JW
and Pomerantz RJ: Potent inhibition of human immunodeficiency virus
type 1 replication by an intracellular anti-Rev single-chain
antibody. Proc Natl Acad Sci USA. 91:5075–5079. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deshane J, Siegal GP, Alvarez RD, Wang MH,
Feng M, Cabrera G, Liu T, Kay M and Curiel DT: Targeted tumor
killing via an intracellular antibody against erbB-2. J Clin
Invest. 96:2980–2989. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cochet O, Kenigsberg M, Delumeau I,
Duchesne M, Schweighoffer F, Tocqué B and Teillaud JL:
Intracellular expression and functional properties of an
anti-p21Ras scFv derived from a rat hybridoma containing specific
lambda and irrelevant kappa light chains. Mol Immunol.
35:1097–1110. 1998. View Article : Google Scholar
|
|
14
|
Lener M, Horn IR, Cardinale A, Messina S,
Nielsen UB, Rybak SM, Hoogenboom HR, Cattaneo A and Biocca S:
Diverting a protein from its cellular location by intracellular
antibodies. Eur J Biochem. 267:1196–1205. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gysin S, Salt M, Young A and McCormick F:
Therapeutic strategies for targeting ras proteins. Genes Cancer.
2:359–372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Russell JS, Lang FF, Huet T, Janicot M,
Chada S, Wilson DR and Tofilon PJ: Radiosensitization of human
tumor cell lines induced by the adenovirus-mediated expression of
an anti-Ras single-chain antibody fragment. Cancer Res.
59:5239–5244. 1999.PubMed/NCBI
|
|
17
|
Van Etten B, Van Tiel ST, Ambagtsheer G,
Eggermont AM and Ten Hagen TL: Isolated limb perfusion based
anti-p21ras gene therapy in a rat rhabdomyosarcoma. Anticancer Res.
24:2295–2301. 2004.PubMed/NCBI
|
|
18
|
Saki M, Toulany M and Rodemann HP:
Acquired resistance to cetuximab is associated with the
overexpression of Ras family members and the loss of
radiosensitization in head and neck cancer cells. Radiother Oncol.
108:473–478. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thor A, Horan Hand P, Wunderlich D, Caruso
A, Muraro R and Schlom J: Monoclonal antibodies define differential
ras gene expression in malignant and benign colonic diseases.
Nature. 311:562–565. 1984. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wakita K, Ohyanagi H, Yamamoto K, Tokuhisa
T and Saitoh Y: Overexpression of c-Ki-ras and c-fos in human
pancreatic carcinomas. Int J Pancreatol. 11:43–47. 1992.PubMed/NCBI
|
|
21
|
Hamdy S, Aprikian A, Begin L, Fair W and
Bazinet M: Ras p21 overexpression is a late event in
prostate-cancer. Int J Oncol. 4:627–631. 1994.PubMed/NCBI
|
|
22
|
Murugan AK, Munirajan AK and Tsuchida N:
Ras oncogenes in oral cancer: The past 20 years. Oral Oncol.
48:383–392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng ZY, Tian L, Bu W, Fan C, Gao X, Wang
H, Liao YH, Li Y, Lewis MT, Edwards D, et al: Wild-Type N-Ras,
Overexpressed in basal-like breast cancer, promotes tumor formation
by inducing IL-8 Secretion via JAK2 activation. Cell Reports.
12:511–524. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hand PH, Thor A, Wunderlich D, Muraro R,
Caruso A and Schlom J: Monoclonal antibodies of predefined
specificity detect activated ras gene expression in human mammary
and colon carcinomas. Proc Natl Acad Sci USA. 81:5227–5231. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gerosa MA, Talarico D, Fognani C, Raimondi
E, Colombatti M, Tridente G, De Carli L and Della Valle G:
Overexpression of N-ras oncogene and epidermal growth factor
receptor gene in human glioblastomas. J Natl Cancer Inst. 81:63–67.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Novara R, Coda R, Martone T and Vineis P:
Exposure to aromatic amines and ras and c-erbB-2 overexpression in
bladder cancer. J Occup Environ Med. 38:390–393. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luo J, Deng ZL, Luo X, Tang N, Song WX,
Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, et al: A protocol
for rapid generation of recombinant adenoviruses using the AdEasy
system. Nat Protoc. 2:1236–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pelletier AJ, Kunicki T and Quaranta V:
Activation of the integrin alpha v beta 3 involves a discrete
cation-binding site that regulates conformation. J Biol Chem.
271:1364–1370. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
He XP, Su CQ, Wang XH, Pan X, Tu ZX, Gong
YF, Gao J, Liao Z, Jin J, Wu HY, et al: E1B-55kD-deleted oncolytic
adenovirus armed with canstatin gene yields an enhanced anti-tumor
efficacy on pancreatic cancer. Cancer Lett. 285:89–98. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kaku Y, Noguchi A, Okutani A, Inoue S,
Tanabayashi K, Yamamoto Y, Hotta A, Suzuki M, Sugiura N and Yamada
A: Altered specificity of single-chain antibody fragments bound to
pandemic H1N1-2009 influenza virus after conversion of the
phage-bound to the soluble form. BMC Res Notes. 5:4832012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu D, Wang C, Li C, Zhang X, Zhang B, Mi
Z, An X and Tong Y: Production and characterization of a humanized
single-chain antibody against human integrin alphav beta3 protein.
J Biol Chem. 286:24500–24507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Biocca S, Neuberger MS and Cattaneo A:
Expression and targeting of intracellular antibodies in mammalian
cells. EMBO J. 9:101–108. 1990.PubMed/NCBI
|
|
33
|
Cattaneo A and Biocca S: Intracellular
Antibodies: Development and Applications. Springer-Verlag; Berlin:
pp. 1–196. 1997, View Article : Google Scholar
|
|
34
|
Thomas SM and Grandis JR: The current
state of head and neck cancer gene therapy. Hum Gene Ther.
20:1565–1575. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Biocca S, Pierandrei-Amaldi P and Cattaneo
A: Intracellular expression of anti-p21ras single chain Fv
fragments inhibits meiotic maturation of xenopus oocytes. Biochem
Biophys Res Commun. 197:422–427. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Marasco WA, Haseltine WA and Chen SY:
Design, intracellular expression, and activity of a human
anti-human immunodeficiency virus type 1 gp120 single-chain
antibody. Proc Natl Acad Sci USA. 90:7889–7893. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rondon IJ and Marasco WA: Intracellular
antibodies (intrabodies) for gene therapy of infectious diseases.
Annu Rev Microbiol. 51:257–283. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Visintin M, Tse E, Axelson H, Rabbitts TH
and Cattaneo A: Selection of antibodies for intracellular function
using a two-hybrid in vivo system. Proc Natl Acad Sci USA.
96:11723–11728. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang W, Sima N, Kong D, Luo A, Gao Q, Liao
S, Li W, Han L, Wang J, Wang S, et al: Selective targeting of
HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic
adenovirus and its enhanced effect with radiotherapy in vitro and
vivo. Cancer Lett. 291:67–75. 2010. View Article : Google Scholar
|
|
40
|
Chang Y, Li Y, Hu J, Guo J, Xu D, Xie H,
Lv X, Shi T and Chen Y: Adenovirus vector-mediated expression of
TMEM166 inhibits human cancer cell growth by autophagy and
apoptosis in vitro and in vivo. Cancer Lett. 328:126–134. 2013.
View Article : Google Scholar
|
